|Bid||61.65 x 900|
|Ask||106.65 x 100|
|Day's Range||85.22 - 93.41|
|52 Week Range||15.17 - 93.41|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||87.63|
Announced Positive Proof-of-Concept Data for ANB020 in Atopic Dermatitis. Announced Positive ANB019 Top-Line Phase 1 Trial Results. Multiple Top-Line Clinical Data Readouts Expected Through the First Half ...
SAN DIEGO, Oct. 12, 2017-- AnaptysBio, Inc., a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced ...
Research Desk Line-up: Merus Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for AnaptysBio, ...
AnaptysBio soared Tuesday after its eczema drug appeared to outperform a potential blockbuster rival drug from Regeneron and Sanofi.
SAN DIEGO, Oct. 10, 2017-- AnaptysBio, Inc., a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced ...
83 Percent of Patients Achieved EASI-50 at Day 29 Following a Single Dose of ANB020 EASI-50 was Observed Early and Persisted Through Day 57 Management to Host Conference Call Today at 8:30 a.m. EDT. SAN ...